Kyverna's CAR-T shows sustained benefit in stiff person syndrome
Kyverna Therapeutics reported positive one-year results in patients with stiff person syndrome, a rare autoimmune disorder affecting about 6,000 people in the US. The data strengthen the company's FDA submission for its CAR-T therapy, which aims to ease painful muscle spasms and stiffness.
Stiff person syndrome is a rare autoimmune neurological disorder that causes progressive muscle rigidity and painful spasms, often severely limiting mobility and daily function. With roughly 6,000 patients in the U.S., treatment options have historically been limited to symptom management rather than addressing the underlying immune dysfunction. Kyverna’s CAR-T therapy is designed to target and reset the faulty immune cells driving the condition.
The company’s newly reported one-year data show sustained benefit, which is a critical milestone for a therapy aiming to provide durable relief. These results strengthen Kyverna’s regulatory submission to the FDA, moving the candidate closer to potential approval. If successful, this would represent a novel cellular approach for an autoimmune disease, expanding CAR-T’s reach beyond oncology into neurology.
This development could offer a meaningful new option for a small but severely affected patient population, potentially reducing reliance on lifelong immunosuppressants. If approved, it may also accelerate research into CAR-T for other autoimmune and neurological disorders, broadening the therapy’s societal impact. However, access and cost could limit widespread use, and long-term safety remains unproven. Patients and clinicians may gain hope, but careful post-market monitoring will be essential.